OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Colt A. Egelston, Weihua Guo, Susan E. Yost, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 3013-3027
Open Access | Times Cited: 12
Colt A. Egelston, Weihua Guo, Susan E. Yost, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 3013-3027
Open Access | Times Cited: 12
Showing 12 citing articles:
Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Biomedicines (2024) Vol. 12, Iss. 2, pp. 369-369
Open Access | Times Cited: 8
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Biomedicines (2024) Vol. 12, Iss. 2, pp. 369-369
Open Access | Times Cited: 8
Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells
Peng Liu, Liwei Zhao, Laurence Zitvogel, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 7-19
Open Access | Times Cited: 12
Peng Liu, Liwei Zhao, Laurence Zitvogel, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 7-19
Open Access | Times Cited: 12
Immunogenic cell stress and death in the treatment of cancer
Hui Pan, Peng Liu, Liwei Zhao, et al.
Seminars in Cell and Developmental Biology (2023) Vol. 156, pp. 11-21
Open Access | Times Cited: 11
Hui Pan, Peng Liu, Liwei Zhao, et al.
Seminars in Cell and Developmental Biology (2023) Vol. 156, pp. 11-21
Open Access | Times Cited: 11
Role of liposomes in chemoimmunotherapy of Breast cancer
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
Meiting Chen, Riqing Huang, Qixiang Rong, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e011314-e011314
Open Access
Meiting Chen, Riqing Huang, Qixiang Rong, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e011314-e011314
Open Access
Conventional type 1 dendritic cells (cDC1) in cancer immunity
Peng Liu, Liwei Zhao, Guido Kroemer, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 10
Peng Liu, Liwei Zhao, Guido Kroemer, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 10
All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality
Jia‐Jin Chen, Tao Han Lee, George Kuo, et al.
Clinical Kidney Journal (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 9
Jia‐Jin Chen, Tao Han Lee, George Kuo, et al.
Clinical Kidney Journal (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 9
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Dandan Feng, Dongqing Pu, Juan Ren, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189193-189193
Closed Access | Times Cited: 3
Dandan Feng, Dongqing Pu, Juan Ren, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189193-189193
Closed Access | Times Cited: 3
Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis
Ping Yang, Guoshuang Shen, Hengheng Zhang, et al.
International Immunopharmacology (2024) Vol. 133, pp. 111961-111961
Closed Access | Times Cited: 2
Ping Yang, Guoshuang Shen, Hengheng Zhang, et al.
International Immunopharmacology (2024) Vol. 133, pp. 111961-111961
Closed Access | Times Cited: 2
Nanomaterials: breaking the bottleneck of breast cancer drug resistance
Chao Guan, Yanbing Han, Ling Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Chao Guan, Yanbing Han, Ling Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
O uso do pembrolizumabe no tratamento do câncer de mama triplo-negativo
Maria Antônia Coelho Moreira, Ana Beatriz de Mello Domingos, Brenda dos Santos Crispim, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 1, pp. 7071-7082
Open Access
Maria Antônia Coelho Moreira, Ana Beatriz de Mello Domingos, Brenda dos Santos Crispim, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 1, pp. 7071-7082
Open Access
Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development
Adam Hermawan, Sisca Ucche, Wilfan Ibadurrahman, et al.
(2024), pp. 377-431
Closed Access
Adam Hermawan, Sisca Ucche, Wilfan Ibadurrahman, et al.
(2024), pp. 377-431
Closed Access
